Cargando…

Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma

SIMPLE SUMMARY: Enhanced expression of mitochondrial ribosomal proteins and marked reprogramming of the mitochondrial network are associated with sorafenib resistance in human cell lines and hepatocarcinoma patients, providing novel actionable targets for increasing therapeutic efficacy. ABSTRACT: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandit, Shusil K., Sandrini, Giada, Merulla, Jessica, Nobili, Valentina, Wang, Xin, Zangari, Alessia, Rinaldi, Andrea, Shinde, Dheeraj, Carbone, Giuseppina M., Catapano, Carlo V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657239/ https://www.ncbi.nlm.nih.gov/pubmed/34885140 http://dx.doi.org/10.3390/cancers13236029

Ejemplares similares

EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
por: Zoma, Marita, et al.
Publicado: (2021)

Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
por: Civenni, Gianluca, et al.
Publicado: (2019)

Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development
por: Sgrignani, Jacopo, et al.
Publicado: (2018)

A functional SNP regulates E-cadherin expression by dynamically remodeling the 3D structure of a promoter-associated non-coding RNA transcript
por: Sharma, Shrikant, et al.
Publicado: (2022)

Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
por: Albino, Domenico, et al.
Publicado: (2021)

The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment
por: Albino, Domenico, et al.
Publicado: (2016)

Metabolomics in oncology
por: Suri, Gurparsad Singh, et al.
Publicado: (2023)

Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers 2020, 12, 176
por: Mapelli, Sarah N., et al.
Publicado: (2020)

A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors)
por: Mapelli, Sarah N., et al.
Publicado: (2020)

Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis
por: Genini, Davide, et al.
Publicado: (2008)

Mitochondrial fission and stemness in prostate cancer
por: Civenni, Gianluca, et al.
Publicado: (2019)

Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

Transcriptional and Non-Transcriptional Functions of PPARβ/δ in Non-Small Cell Lung Cancer
por: Genini, Davide, et al.
Publicado: (2012)

Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death
por: Xie, Linna, et al.
Publicado: (2018)

Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3
por: Hu, Zongqiang, et al.
Publicado: (2023)

Vulnerability genes or plasticity genes?
por: Belsky, J, et al.
Publicado: (2009)

Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3
por: Toledo, Míriam, et al.
Publicado: (2014)

Deciphering the complexity of human non-coding promoter-proximal transcriptome
por: Mapelli, Sarah N, et al.
Publicado: (2019)

Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis
por: Soukupova, Jitka, et al.
Publicado: (2017)

Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK
por: Lee, Seulki, et al.
Publicado: (2018)

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells
por: Li, Yu, et al.
Publicado: (2020)

Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation
por: Jiang, Yuchuan, et al.
Publicado: (2021)

Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma
por: Siddharth, Sumit, et al.
Publicado: (2022)

Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1–mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma
por: Saraswati, Sarita, et al.
Publicado: (2019)

Effects of miR-193a and sorafenib on hepatocellular carcinoma cells
por: Salvi, Alessandro, et al.
Publicado: (2013)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014)

Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma
por: Li, Jun, et al.
Publicado: (2018)

Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
por: Zhao, Weijia, et al.
Publicado: (2020)

LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells
por: Liu, Yuan, et al.
Publicado: (2020)

Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation
por: Wang, Xiaoli, et al.
Publicado: (2020)

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]
Publicado: (2020)

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction]
Publicado: (2022)

MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis
por: Shi, Chaoran, et al.
Publicado: (2022)

Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells
por: Napoli, Sara, et al.
Publicado: (2006)

Lectin Pathway of Complement Activation Is Associated with Vulnerability of Atherosclerotic Plaques
por: Fumagalli, Stefano, et al.
Publicado: (2017)

The JAK/STAT Pathway Is Involved in Synaptic Plasticity
por: Nicolas, Céline S., et al.
Publicado: (2012)

Defining and Measuring Vulnerability in Young People
por: Arora, Shilpa Khanna, et al.
Publicado: (2015)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_j7434crgbnoo5m5fq2ahfcoad6